BRPI0408506A - processos para isolamento de forma i cristalina de 5-azacitidina - Google Patents

processos para isolamento de forma i cristalina de 5-azacitidina

Info

Publication number
BRPI0408506A
BRPI0408506A BRPI0408506-0A BRPI0408506A BRPI0408506A BR PI0408506 A BRPI0408506 A BR PI0408506A BR PI0408506 A BRPI0408506 A BR PI0408506A BR PI0408506 A BRPI0408506 A BR PI0408506A
Authority
BR
Brazil
Prior art keywords
azacytidine
processes
isolation
crystalline form
crystaline
Prior art date
Application number
BRPI0408506-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dumitru Ionescu
Peter Blumbergs
Gary L Silvey
Original Assignee
Pharmion Corp
Ash Stevens Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408506(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmion Corp, Ash Stevens Inc filed Critical Pharmion Corp
Publication of BRPI0408506A publication Critical patent/BRPI0408506A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
BRPI0408506-0A 2003-03-17 2004-03-16 processos para isolamento de forma i cristalina de 5-azacitidina BRPI0408506A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,530 US6943249B2 (en) 2003-03-17 2003-03-17 Methods for isolating crystalline Form I of 5-azacytidine
PCT/US2004/007896 WO2004082822A2 (fr) 2003-03-17 2004-03-16 Procedes permettant d'isoler la forme i cristalline de la 5-azacytidine

Publications (1)

Publication Number Publication Date
BRPI0408506A true BRPI0408506A (pt) 2006-03-14

Family

ID=32987551

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408506-0A BRPI0408506A (pt) 2003-03-17 2004-03-16 processos para isolamento de forma i cristalina de 5-azacitidina

Country Status (16)

Country Link
US (5) US6943249B2 (fr)
EP (3) EP1608634B1 (fr)
JP (1) JP4792550B2 (fr)
AU (2) AU2004222274B2 (fr)
BR (1) BRPI0408506A (fr)
CA (1) CA2518973A1 (fr)
CY (2) CY1114213T1 (fr)
DK (2) DK2181988T3 (fr)
EC (1) ECSP056023A (fr)
ES (2) ES2425474T3 (fr)
HU (1) HUE028268T2 (fr)
MX (1) MXPA05009969A (fr)
PL (2) PL2181988T3 (fr)
PT (2) PT1608634E (fr)
SI (2) SI1608634T1 (fr)
WO (1) WO2004082822A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902490A (nl) * 1989-10-06 1991-05-01 Leonardus Mathijs Marie Nevels Werkwijze voor het reinigen van rookgassen.
EP1300992B1 (fr) * 2001-10-08 2005-12-28 Alcatel Procédé pour répartir la charge entre un jeu de resources partagées par l'application d'un jeu de fonctions de distribution de la charge et réseau pour mettre en application un tel procédé
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
EP2073807A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP2644614A3 (fr) 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Formes à l'état solide de 5-azacytidine et leurs procédés de préparation
US20110288042A1 (en) * 2007-08-02 2011-11-24 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
KR20100072230A (ko) * 2007-09-26 2010-06-30 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 아자시티딘 유사체 및 이의 용도
WO2009058394A1 (fr) * 2007-11-01 2009-05-07 Celgene Corporation Analogues de la cytidine destinés au traitement de syndromes myélodysplasiques
PL2299984T3 (pl) * 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (fr) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Procédé de préparation d'azacitidine et polymorphes
ES2487525T3 (es) * 2008-08-08 2014-08-21 Scinopharm Taiwan Ltd. Procedimiento para preparar nucleósidos de 5-azacitosina y sus derivados
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
RU2013148580A (ru) 2011-03-31 2015-05-10 Селджин Интернешнл Сарл Синтез 5-азацитидина
WO2013022872A1 (fr) 2011-08-10 2013-02-14 Celgene Corporation Biomarqueurs de méthylation génique et leurs procédés d'utilisation
MX2014003467A (es) 2011-09-23 2014-07-30 Celgene Corp Romidepsina y 5-azacitidina para el tratamiento de linfoma.
JP2014526564A (ja) 2011-09-26 2014-10-06 セルジーン コーポレイション 化学療法抵抗性癌の併用療法
CA2854461C (fr) 2011-11-03 2021-01-19 Millennium Pharmaceuticals, Inc. Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypomethylation
WO2013080221A2 (fr) * 2011-12-01 2013-06-06 Hetero Research Foundation Procédé de purification d'alvimopan
EP2911648B1 (fr) * 2012-10-25 2017-02-01 Fresenius Kabi Oncology Limited Composition pharmaceutique stable de 5-aza-2'-désoxycitidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
WO2014076616A2 (fr) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations de 5-azacytidine
WO2014160698A1 (fr) 2013-03-26 2014-10-02 Celgene Corporation FORMES SOLIDES COMPRENANT DE LA 4-AMINO-1-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE ET UN CO-AGENT DE FORMATION, COMPOSITIONS ET LEURS PROCÉDÉS D'UTILISATION
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
EA201790439A1 (ru) 2014-08-22 2017-07-31 Селджин Корпорейшн Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
EP3362070B1 (fr) 2015-10-15 2021-01-27 Celgene Corporation Combinaison d'un inhibiteur de l'isocitrate dehydrogenase 2 mutante avec l'azacitidine et son utilisation pour le traitement de la leucémie myélogène aiguë
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
KR20190068544A (ko) * 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途
WO2022251663A2 (fr) * 2021-05-27 2022-12-01 Emory University Nouveaux agents viraux anti-arn universels

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (fr) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) * 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
HUP0001107A3 (en) * 1996-10-16 2003-01-28 Icn Pharmaceuticals Inc Costa Monocyclic l-nucleosides, analogs and pharmaceutical compositions thereof
CA2375601C (fr) * 1999-06-03 2008-07-29 Eisai Co., Ltd. Cristaux composes de carbapenem et preparations pour injection
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP4870320B2 (ja) * 2000-09-07 2012-02-08 株式会社カネカ ヒドロキシカルボン酸の結晶化法
CA2788498C (fr) 2001-03-01 2016-02-16 Gilead Sciences, Inc. Formes cristallines polymorphes et autres de ftc cis
CA2499036A1 (fr) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1, 3, 5-triazines destinees au traitement de maladies virales
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
EP1517893A2 (fr) 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Procede de production de levetiracetam
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6877855B2 (en) 2003-07-08 2005-04-12 Dave Ng Spectacles with peripheral lens support
CN101856348A (zh) * 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2008028193A2 (fr) * 2006-09-01 2008-03-06 Pharmion Corporation Formulations orales d'analogues de cytidine administrées dans le côlon
EP2644614A3 (fr) * 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Formes à l'état solide de 5-azacytidine et leurs procédés de préparation
US20080182806A1 (en) * 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
US20110288042A1 (en) 2007-08-02 2011-11-24 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (fr) * 2007-10-10 2009-04-15 Cilag AG Procédé pour la production de nucléosides par glycosylation directe de la base nucléosidique
WO2009058394A1 (fr) * 2007-11-01 2009-05-07 Celgene Corporation Analogues de la cytidine destinés au traitement de syndromes myélodysplasiques
PL2299984T3 (pl) * 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (fr) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Procédé de préparation d'azacitidine et polymorphes
CN102171233A (zh) * 2008-08-06 2011-08-31 西科尔公司 制备氮杂胞苷中间体的方法
ES2487525T3 (es) * 2008-08-08 2014-08-21 Scinopharm Taiwan Ltd. Procedimiento para preparar nucleósidos de 5-azacitosina y sus derivados
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (fr) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Compositions stables à base d'azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
US7700770B2 (en) 2010-04-20
US20120245342A1 (en) 2012-09-27
EP2181988A1 (fr) 2010-05-05
CA2518973A1 (fr) 2004-09-30
US20040186284A1 (en) 2004-09-23
JP2006523210A (ja) 2006-10-12
US20100292180A1 (en) 2010-11-18
US8481715B2 (en) 2013-07-09
AU2010241198B2 (en) 2012-05-10
EP1608634A2 (fr) 2005-12-28
AU2010241198A1 (en) 2010-11-25
SI1608634T1 (sl) 2013-09-30
ES2575535T3 (es) 2016-06-29
HUE028268T2 (en) 2016-12-28
AU2004222274B2 (en) 2010-11-04
US8211862B2 (en) 2012-07-03
EP1608634B1 (fr) 2013-05-22
PL1608634T3 (pl) 2013-10-31
ECSP056023A (es) 2006-01-27
AU2004222274A1 (en) 2004-09-30
MXPA05009969A (es) 2006-02-17
PL2181988T3 (pl) 2016-11-30
DK2181988T3 (en) 2016-06-06
ES2425474T3 (es) 2013-10-15
CY1117639T1 (el) 2017-04-26
CY1114213T1 (el) 2016-08-31
PT2181988E (pt) 2016-06-15
EP2181988B1 (fr) 2016-05-11
WO2004082822A2 (fr) 2004-09-30
PT1608634E (pt) 2013-08-27
DK1608634T3 (da) 2013-08-12
SI2181988T1 (sl) 2016-09-30
EP2266965A1 (fr) 2010-12-29
JP4792550B2 (ja) 2011-10-12
EP1608634A4 (fr) 2006-03-15
WO2004082822A3 (fr) 2005-07-07
US8975392B2 (en) 2015-03-10
US20050272675A1 (en) 2005-12-08
US20130274459A1 (en) 2013-10-17
US6943249B2 (en) 2005-09-13

Similar Documents

Publication Publication Date Title
BRPI0408506A (pt) processos para isolamento de forma i cristalina de 5-azacitidina
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
ECSP045088A (es) Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ECSP066667A (es) Derivados de ciclohexano espirociclicos
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
UA94833C2 (en) Substituted bicyclolactams
WO2007009109A3 (fr) Composes antiviraux
ATE433447T1 (de) Pyrimiidinverbindungen
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
WO2008013838A3 (fr) Dérivés de pyridizinone
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
WO2004106293A3 (fr) Composes tricycliques a base d'oxazolo[4,5-b]pyridine condensee a un imidazo et de thiazolo[4,5-b]pyridine condensee a un imidazo, et compositions pharmaceutiques renfermant ceux-ci
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
WO2005075467A3 (fr) Formes cristallines de zolmitriptan
TW200420541A (en) Crystalline forms
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
RS53211B (en) PYRIDO [2,3-d] PYRIMIDINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN THERAPY
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
WO2005011609A3 (fr) Composes tricycliques a base de triazolopurine et compositions pharmaceutiques contenant ces composes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASH STEVENS INC. (US) , COBALT ACQUISITION LLC (CH

Free format text: TRANSFERIDO POR FUSAO DE: PHARMION CORPORATION

B25D Requested change of name of applicant approved

Owner name: ASH STEVENS INC. (US) , PHARMION LLC (CH)

Free format text: NOME ALTERADO DE: COBALT ACQUISITION LLC

B25A Requested transfer of rights approved

Owner name: ASH STEVENS INC. (US) , CELGENE INTERNATIONAL SARL

Free format text: TRANSFERIDO DE: PHARMION LLC

B25A Requested transfer of rights approved

Owner name: CELGENE INTERNATIONAL SARL (CH)

Free format text: TRANSFERIDO DE: ASH STEVENS INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]